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Abstract The discovery of molecules with anti-angio-
genic properties has led to promising new strategies for the
treatment of diseases characterized by excessive new ves-
sel growth, such as cancer and haemangioma. We have
assessed the effects of DNA-damaging and cytoskeletal-
disrupting agents in vitro on several endothelial cell func-
tions. We report that bleomycin, mitomycin C and
cytoskeletal-disrupting drugs (2-methoxyestradiol, taxol,
vincristine, vinblastine, colchicine, nocodazole, and cyto-
chalasin D) exhibit anti-angiogenic activities of varying
potency. Bleomycin and the various cytoskeletal-disrupting
drugs inhibited endothelial cell migration, while mitomy-
cin C had a marginal effect. Both DNA-damaging and
cytoskeletal-disrupting drugs decreased endothelial cell
growth in a dose-dependent manner, and this was accom-
panied by the induction of apoptosis. The growth inhibitory
and apoptotic effects of cytoskeletal-disrupting drugs were
the most pronounced. We also show that both classes of
drugs inhibited capillary-like tube formation in an assay of
in vitro angiogenesis, with cytoskeletal-disrupting agents
inhibiting in vitro angiogenesis with greater potency. A
targeted approach incorporating several compounds with
different mechanisms of action may be useful for the
treatment of angiogenesis-dependent diseases such as
hemangiomas of infancy.
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Introduction
Hemangiomas are benign vascular tumors frequently
encountered in pediatrics, and although benign, may present
serious complications [1–3]. Although several approaches
have been tried, there is to date no definitive treatment for
hemangiomas. Recently however, the effectiveness of int-
ralesional bleomycin was evaluated by the Pretoria Vascular
Malformation Study Group in 37 hemangioma patients.
Complete resolution or significant improvement was seen in
87% of patients [2]. Hemangioma development is associated
with an imbalance between negative and positive regulators
of angiogenesis, and light microscopic examination of hae-
mangioma tissue has demonstrated that the hallmark of a
growing hemangioma is proliferating endothelial cells [4, 5].
Furthermore, vascular endothelial growth factor (VEGF)
and basic fibroblast growth factor (bFGF), have been
implicated in the pathogenesis of these lesions [6].
The process of angiogenesis is characterized by altera-
tions in at least three endothelial cell functions, each of
which is a potential target for anti-angiogenic strategies: (1)
modulation of interactions with the extracellular matrix, (2)
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an initial increase and subsequent decrease in migration,
and (3) an increase in proliferation, which provides new
cells for the growing and elongating vessel [7]. Angiogen-
esis is also dependent on the suppression of endothelial cell
apoptosis [8–10]. The recognition that excessive angio-
genesis underlies hemangioma development, offers an
opportunity for the development of therapeutic strategies
based on the inhibition of angiogenesis.
Therapeutic strategies that target angiogenesis have
relied on an understanding of the mechanisms of action of
anti-angiogenic molecules and a re-evaluation of conven-
tional chemotherapeutic drugs [11]. With respect to the re-
examination of ‘classical’ anticancer agents, mitomycin C
has previously been shown to inhibit human microvascular
endothelial cell growth [12]. However, the anti-angiogenic
effects of both mitomycin C and bleomycin have not been
well documented.
Microtubule-disrupting agents (including 2-methoxy-
estradiol, taxol, vincristine, vinblastine, and colchicine)
and the microfilament-disrupting drug, cytochalasin D,
have been reported to affect certain elements of the
angiogenic process, such as endothelial cell migration and
in vitro capillary-like tube formation [13–15].
Previously, drugs with anti-angiogenic activity were
developed and tested individually. However, because of the
complexity of the angiogenesis process and the number of
regulatory molecules involved in blood vessel growth, a
multi-drug approach may be required to optimize the anti-
angiogenic effect of therapy aimed at treating vascular
tumors of infancy.
In the present study we evaluated and compared the
effects of bleomycin, mitomycin C and cytoskeletal-dis-
rupting drugs (2-methoxyestradiol, taxol, vincristine,
vinblastine, colchicine, nocodazole, and cytochalasin D),
on two critical endothelial cell functions namely, endo-
thelial cell migration and growth, which characterize
angiogenesis. The effect of these drugs on endothelial cell
apoptosis and in vitro angiogenesis were also assessed. To
our knowledge, this is the first comparative study under-
taken to investigate the anti-angiogenic effects of these
drugs under similar conditions.
Materials and methods
Cell culture
Adrenal cortex-derived bovine microvascular endothelial
(BME) cells were maintained in a 37C incubator in a
humidified atmosphere containing 5% CO2. The cells were
grown in a-modified minimum essential medium (a-MEM)
supplemented with 15% donor calf serum (DCS), penicillin
(500 U/ml), and streptomycin (100 lg/ml).
Cell migration
Confluent monolayers of BME cells in 35 mm tissue cul-
ture dishes were wounded with a blade to mark the initial
wound edge. Wounded cultures were washed twice with
serum-free a-MEM, then serum-free a-MEM/0.1% gelatin
and test drugs (bleomycin, mitomycin C, 2-methoxyestra-
diol (2-ME), taxol, colchicine, nocodazole, and,
cytochalasin D) were added at the indicated concentrations
(Figs. 1, 2). After 15 h, monolayers were stained with
0.1% crystal violet in 20% methanol for 30 min. Fields
measuring 1.0 9 1.4 mm were selected and further sub-
divided into smaller fields measuring 100 lm each. The
fields were then photographed under phase-contrast using a
Nikon Diaphot TMD inverted photomicroscope (Nikon,
Tokyo, Japan). The total number of cells which had crossed
the original wound edge was determined. At least six wells
were analyzed from each treatment per experiment. Results
were from at least two independent experiments.
Cell growth
Cell growth studies were performed to assess the effects of
test drugs on BME cell growth using a FACScan Analyzer.
Briefly, BME cells were seeded into gelatine-coated 24
well-plates at a density of 10,000 cells/well. Cells were
grown in a-MEM supplemented with 5% DCS. After 24 h,
fresh medium was added together with test drugs (bleo-
mycin, colchicine, 2-methoxyestradiol, and taxol). Control
cells were exposed to drug vehicles. Two days later,
medium and test drugs were renewed, and further after
2 days, cells were trypsinised and counted in a FACScan
Analyzer (Becton–Dickinson, San Jose´, CA). Results rep-
resent the mean ± SEM. Three wells were analyzed for
each concentration. Data shown are representative of least
two independent experiments.
Analysis of DNA fragmentation
Confluent BME cell monolayers in 60 mm tissue culture
dishes (1 9 106 cells/plate) were incubated with test drugs/
vehicles for 48 h. At the end of the incubation, floating
cells were recovered from culture media by centrifugation,
and adherent cells were washed twice with PBS.
Floating and adherent cells were lysed together in 250 ll/
tissue culture dish of 20 mM Tris–HCl, pH 7.4, 5 mM
EDTA, pH 7.4, 0.4% Triton X-100. Cell lysates were cen-
trifuged at 13,000 rpm for 30 min at 4C to pellet nuclei.
Supernatants were extracted with equal volumes of
phenol–chloroform, precipitated with 0.5 volume of 7.5 M
ammonium acetate, pH 7.5, and 3 volumes of ethanol, and
then centrifuged at 13,000 rpm for 30 min at 4C. Samples
were left overnight at -20C. Pellets were resuspended in
82 Angiogenesis (2009) 12:81–90
123
Fig. 1 Effects of bleomycin,
mitomycin C, and cytoskeletal-
disrupting drugs on BME cell
migration. Confluent BME cell
monolayers were wounded with
a blade to mark the initial
wound edge and washed. Cells
were then treated with the
indicated test substances (a–i).
After 15 h, control and treated
cultures were fixed and stained,
and subsequently viewed with a
light microscope. Within the
wound, seven sequential
100 lm-deep fields parallel to
the original wound measuring
1.0 9 1.4 mm were delineated
from the original normal edge.
The total number of cells in
each of the field was
determined. At least six wells
were analyzed from each
treatment per experiment. Data
shown is from at least two
separate experiments per drug
and concentration
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10 mM Tris–HCl, pH 8.0,1 mM EDTA, pH 8.0, contain-
ing DNase-free pancreatic ribonuclease (20 lg/ml),
incubated at 37C for 30 min and loaded onto 1.8% aga-
rose gels containing ethidium bromide (1 lg/ml). Samples
were electrophoresed at 10 V/cm for 2 h. DNA was visu-
alized by UV fluorescence. Results were from at least two
separate experiments.
Acridine-orange staining
Cells were seeded in 35 mm diameter wells at a density of
20,000 cells per well. After 24 h, BME cells were grown in
the presence of the various drug preparations/vehicles for
48 h. Cells were harvested as follows: medium and floating
cells were transferred to 15 ml tubes. The rest of the
adherent cells were detached with 0.25% trypsin-1 mM
EDTA. The floating and detached cells from the same
sample were pooled together in 15 ml tubes, pelleted by
centrifugation at 1,000 rpm for 5 min using a Beckman
Model centrifuge, and cell pellets were washed with 1 ml
PBS, and subsequently re-suspended in 25 ll PBS. Cells
were then incubated with 10 lg/ml acridine orange for
5 min. Stained cell suspensions (10 ll) were placed on
microscope slides and covered with coverslips. Cells were
viewed and counted using a Zeiss Axiovert microscope
(Carl Zeiss, Jena, Germany) at 4009 magnification. Pic-
tures were taken with a Nikon digital camera. Apoptosis
was identified as nuclear chromatin condensation. Ran-
domly selected microscopic fields were examined, and the
percentage of cells undergoing apoptosis in each field was
determined. Results were expressed as the mean percentage
(±SD) of cells with evidence of apoptosis. Tests were done
in triplicate.
Preparation of collagen gels
The in vitro angiogenesis assay was performed using BME
cells as previously described by Montesano and Orci
(1987) [16]. Type 1 collagen was solubilized by stirring
adult rat tail tendons for 48 h at 4C in sterile 1:1000 (vol/
vol) acetic acid solution (300 ml for 1 mg of collagen).
The resulting solution was filtered through sterile triple
gauze and centrifuged at 16,0009g for 1 h at 4C.
Eight volumes of the supernatant were mixed with 1
volume of 109 minimum essential medium and 1 volume
of sodium bicarbonate (11.76 mg/ml) in a sterile flask
placed on ice, to prevent immediate gelation. The cold
mixture was then dispensed into 18 mm tissue culture
wells and allowed to gel for 10 min at 37C.
In vitro angiogenesis assay
BME cells were seeded onto collagen gels at 1.0 9 105
cells/well in 500 ll a-MEM supplemented with 5% DCS,
and were grown to confluence (3–4 days), at which point
treatment with growth factors and/or drugs was begun.
Medium and treatments were renewed every second day.
After 6 days, cultures were fixed with 2.5% glutaralde-
hyde in 100 mM sodium cacodylate buffer (pH 7.4).
Fixed cultures were photographed for quantification of
invasion.
Quantification of invasion
Three randomly selected fields measuring 1.0 9 1.4 mm
were photographed in each well at a single level beneath
the surface monolayer by phase contrast microscopy.
Fig. 2 Effect of bleomycin,
mitomycin C, and cytoskeletal-
disrupting drugs on BME cell
growth. Cells were seeded at a
density of 10,000 cells per well
in 24-well culture plates and
exposed to test drugs indicated
in a–c for 4 days. At
termination, drug-treated and
control cells were counted
following trypsinization using a
FACScan analyser. Three wells
were analyzed for each
concentration. Results represent
the mean ± SEM. Data shown
is from least two independent
experiments per drug and
concentration. * Significant
difference between the number
of control and treated cells:
P \ 0.05
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Invasion was quantitated by determining the total additive
sprout length in lm ± SEM, and the results were from at
least two separate experiments.
Statistical analysis
Statistics were performed using 1-way ANOVA, and where
statistical significance was reached, pair-wise multiple
comparisons were made using an ad hoc test (Bonferroni’s
method). When data were not normally distributed,
ANOVA on ranks was performed, followed by pair-wise
comparisons, again employing the Bonferroni approach.
Significance was designated as P \ 0.05.
Results
Effects on endothelial cell migration
Bleomycin inhibited BME cell migration at a dose of
100 lg/ml, while no significant inhibition of endothelial
cell migration occurred following exposure of cells to
mitomycin C (Fig. 1a, b). Inhibition of endothelial cell
migration following exposure to colchicine occurred at a
dose of 1 lM (Fig. 1c) while taxol inhibited cell migration
at 0.1 lM (Fig. 1d). Nocodazole, cytochalasin D, vinblas-
tine, vincristine and 2-ME inhibited BME cell migration in
a dose-dependent manner (Fig. 1e–i). Both vinblastine and
Table 1 Effects of test drugs on endothelial cell growth
Drug Cell type IC50
Bleomycin
Bleomycin ? bFGF
BME cells 0.105 lM
0.053 lM
Mitomycin C
Mitomycin C ? bFGF
BME cells 0.149 lM
0.180 lM
2-Methoxyestradiol
2-Methoxyestradiol ? bFGF
BME cells 0.398 lM
0.018 lM
Taxol
Taxol ? bFGF
BME cells 0.040 lM
0.063 lM
Vincristine
Vincristine ? bFGF
BME cells 0.004 lM
0.004 lM
Vinblastine
Vinblastine ? bFGF
BME cells 0.690 nM
0.900 nM
Colchicine
Colchicine ? bFGF
BME cells 0.032 lM
0.017 lM
Nocodazole
Nocodazole ? bFGF
BME cells 0.031 lM
0.022 lM
Cytochalasin D
Cytochalasin D ? bFGF
BME cells 0.063 lM
ND
Results are expressed as IC50 values or the concentration of the
respective substance, which resulted in half the numbers of cells being
present at the end of the experiment that were obtained in the control.
Data is representative of at least two independent experiments per
drug and concentration
ND Not determined
bFGF basic fibroblast growth factor
Fig. 3 Analysis of
internucleosomal fragmentation
in DNA preparations following
exposure to bleomycin,
mitomycin C and cytoskeletal-
disrupting drugs for 48 h.
Representative experiments are
shown
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vincristine had a more profound effect by inhibiting cell
migration at doses of 0.011 and 0.001 lM, respectively.
The doses at which test drugs induced significant inhibition
of endothelial cell migration are summarized in Table 4.
Effects on endothelial cell ‘‘growth’’
Cell ‘‘growth’’, as determined in the assays performed,
measures the absolute number of cells after a given time
period under defined conditions. It does not distinguish
between cell proliferation and cell death, but is the net
result of the two. It is therefore a crude test aimed at
determining whether the test substance affects the cells in
question, and the cause for any variation needs to be
determined in greater detail.
Bleomycin and mitomycin C inhibited BME cell growth
(Fig. 2a), with IC50 values of 0.16 lg/ml (0.11 lM) and
0.05 lg/ml (0.15 lM), respectively, (Table 1). Bleomycin
also inhibited bFGF-induced BME cell growth, with the
inhibitory effect being more pronounced at 100 lg/ml. The
level of 2-ME-induced cell growth inhibition was less than
that seen with taxol (Fig. 2b). A maximum inhibitory effect
following exposure to 2-ME occurred at a dose of 10 lM,
while taxol exerted a maximum inhibitory effect on
endothelial cell growth at a dose of 1 lM. Colchicine
induced a dose-dependent inhibition of BME cell growth
with an IC50 of 0.032 lM (Table 1). The effects of col-
chicine on BME cell growth were mimicked by nocodazole
(IC50 0.031 lM). Cytochalasin D induced a significant
decrease in cell numbers at doses of 1 lM and above
(Fig. 2b).
Vinblastine and vincristine inhibited growth of endo-
thelial cells in a dose-dependent manner (Fig. 2c);
however, vinblastine was more potent as shown by the IC50
values of 0.004 lM and 0.690 nM, respectively, (Table 1).
Effects on endothelial cell apoptosis
DNA isolated from untreated BME cells was compared
with DNA from cells exposed to varying concentrations of
the different drugs. Bleomycin induced DNA strand breaks
in a dose-dependent manner (Fig. 3). The intensity of the
ladders increased with increasing drug concentrations, with
the most intense ladders observed following exposure to 30
and 100 lg/ml bleomycin. 2-ME, taxol, Colchicine, no-
codazole and cytochalasin D also induced DNA strand
breaks (Fig. 3). In 2-ME treated cells, internucleosomal
DNA fragmentation was detected only after exposure to the
highest dose (10 lM), while colchicine and taxol induced
DNA strand breaks at doses of only 100 nM.
The percentage of acridine orange labeled-BME cells
was increased in cultures exposed to the various test drugs
(Table 2), indicating that they induced apoptosis.
Effects on in vitro angiogenesis
Control untreated BME cells formed a monolayer on the
surface of 3-dimensional collagen gels (Fig. 4a) with a
cobblestone appearance, while BME cells treated with a
combination of 10 ng/ml bFGF and 30 ng/ml VEGF
invaded the underlying gel and organized into branching
cords inside the collagen matrix (Fig. 4b); few such cords
were observed in cultures treated with bleomycin alone or
Table 2 Induction of apoptosis in BME cells
% Acridine orange-labeled cells
Control 5.92 ± 4.28
Bleomycin
0.1 lg/ml 11.26 ± 9.62
10 lg/ml 21.03 ± 11.61*
100 lg/ml 41.72 ± 16.35*
Mitomycin
0.1 lg/ml 22.55 ± 18.60*
1 lg/ml 33.76 ± 18.21*
10 lg/ml 58.10 ± 20.42*
Colchicine
0.01 lM 6.21 ± 4.02
1 lM 33.52 ± 11.26*
10 lM 31.05 ± 9.65*
Nocodazole
0.01 lM 12.53 ± 9.36
1 lM 43.87 ± 9.75*
10 lM 40.25 ± 8.15*
Taxol
0.01 lM 17.82 ± 6.22*
1 lM 45.37 ± 10.80*
10 lM 44.00 ± 8.01*
2-ME
0.01 lM 18.57 ± 8.05*
1 lM 32.81 ± 12.50*
10 lM 52.21 ± 10.02*
Vincristine
0.001 ng/ml 5.92 ± 6.10
0.1 ng/ml 5.87 ± 4.25
10 ng/ml 27.26 ± 11.20*
Vinblastine
0.001 ng/ml 6.04 ± 8.22
0.1 ng/ml 12.01 ± 8.75
10 ng/ml 37.20 ± 11.26*
Confluent monolayers of BME cells were exposed to the agents
indicated above, and apoptosis (acridine orange labeling) was deter-
mined after 48 h. Values are the mean ± SD. Results are pooled from
at least three separate experiments per drug and concentration. An
average of 12 fields was analyzed per treatment dose in each exper-
iment. * Significant difference between control and drug-treated cells:
P \ 0.05
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with a combination of bFGF/VEGF and bleomycin
(Fig. 4c–d).
There were no endothelial cell cords in cultures exposed
to colchicines or 2-ME or only (Fig. 4e, g); however,
colchicine- and bleomycin-treated cells appeared similar in
morphology to control cells, while 2-ME-treated cells
appeared polygonal in morphology (e). Quantitative anal-
ysis of in vitro tube formation showed that bleomycin,
mitomycin C, colchicine, 2-ME, nocodazole, cytochalasin
D and taxol inhibited bFGF-induced BME cell cord for-
mation (Fig. 5a–d; Tables 3, 4).
Discussion
Herein we describe studies undertaken to compare the anti-
angiogenic effects of DNA-damaging drugs and agents that
affect cytoskeletal dynamics. Our observations revealed
that bleomycin, a DNA-damaging chemotherapeutic drug,
as well as cytoskeletal-disrupting agents (2-methoxyestra-
diol, taxol, vincristine, vinblastine, colchicine, nocodazole,
and cytochalasin D) inhibited BME cell migration. How-
ever, the inhibitory effects of cytoskeletal-disrupting drugs
on endothelial cell migration were more pronounced. In
addition to endothelial cell migration, angiogenesis is
characterized by endothelial cell growth, sometimes
uncontrolled, as well as capillary-like tube formation.
Therefore further studies on the anti-angiogenic effects of
test drugs were evaluated using assays of cell growth and in
vitro tube formation.
Cell ‘‘growth’’ studies revealed a dose-dependent
reduction in the percentage of viable BME cells in bleo-
mycin- and mitomycin C-treated cultures. Cytoskeletal-
disrupting drugs, with the exception of 2-ME, caused a
Fig. 4 Effects of bleomycin,
colchicine, 2 methoxyestradiol
(2ME) and Taxol on BME cells
grown on collagen gel. Cells
seeded on top of type I collagen
gel were exposed to drugs in the
presence or absence of bFGF for
6 days. Medium and treatments
were renewed every second day.
At termination, cultures were
fixed with 2.5% glutaraldehyde;
three randomly selected fields
measuring 1.0 9 1.4 mm were
then photographed in each well
at a single level beneath the
surface monolayer by phase
contrast microscopy. Results are
from at least two separate
experiments per drug and
concentration. Bar = 100 lm
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reduction in BME cell numbers in a dose-dependent
manner, and with greater potency than bleomycin and
mitomycin C. Bleomycin, 2-ME, colchicine and nocodaz-
ole induced a more pronounced reduction in cell numbers
in bFGF-treated BME cells than when added alone.
Therefore, cytokine stimulated BME cells appear to be
more susceptible to the growth inhibitory effects of these
drugs. Previous reports suggest that bFGF may have a role
in the development of various tumors, including heman-
giomas of infancy [5].
Bleomycin has recently been employed in the treatment
of juvenile hemangiomas, with promising results [17–19].
Initially, the effectiveness of bleomycin in inducing hem-
angioma regression was attributed to the sclerosing effect of
the drug on the vascular endothelium [18]. More recently
however, it was shown that bleomycin prevents human
hemangioma growth in vitro by inhibiting neovessel growth
[20]. Bleomycin’s antiproliferative effects on growth fac-
tor-stimulated endothelial cells could be partly responsible
for its ability to inhibit hemangioma growth in patients.
Also, the ability of 2-ME, colchicine and nocodazole to
inhibit endothelial cell growth in the presence of this potent
angiogenic growth factor may be translated in the clinical
setting to enable effective growth inhibition in juvenile
hemangiomas.
To determine the mode by which these test drugs
decreased cell numbers, their effect on apoptosis was
assessed. When DNA extracted from BME cells treated
with bleomycin, mitomycin, 2-methoxyestradiol, taxol,
colchicine, nocodazole, or cytochalasin D was analyzed
using gel electrophoresis, characteristic internucleosomal
‘‘ladders’’ of DNA fragments were found. These ladders
Fig. 5 Quantitative analysis of the effects of bleomycin, mitomycin
C, and cytoskeletal-disrupting drugs on in vitro angiogenesis. BME
cells were seeded on collagen gel in the presence of bFGF alone or
bFGF and test drugs. After 6 days, invasion was quantitated by
determining the total additive sprout length in lm ± SEM, and
results are from at least two separate experiments. Two wells were
analyzed for each concentration. Data shown is from at least two
independent experiments per drug and concentration. *Significant
difference in total additive sprout length between untreated (0 lg/ml)
and drug-treated cells: P \ 0.05
Table 3 Quantitative analysis of the effects of test drugs on in vitro
angiogenesis
Drug Cell type IC50
Bleomycin BME cells 11.850 lM
Mitomycin C BME cells 2.340 lM
2-Methoxyestradiol BME cells 0.400 lM
Taxol BME cells 0.010 lM
Vincristine BME cells 0.860 nM
Vinblastine BME cells 0.870 nM
Colchicine BME cells 0.016 lM
Nocodazole BME cells 0.017 lM
Cytochalasin D BME cells 0.017 lM
Results are presented as IC50 values, the drug concentration at which
50% inhibition of capillary-like tube formation was observed. Data
shown is from at least two independent experiments per drug and
concentration
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were not observed in control samples. Results from cul-
tures that were exposed to vincristine and vinblastine were
inconclusive. Internucleosomal DNA fragmentation is a
biochemical indicator of apoptosis [21, 22].
In addition to DNA fragmentation, chromatin conden-
sation is an early and relatively unequivocal hallmark of
apoptosis [22]. Therefore, drug-induced apoptosis was
further evaluated using the acridine orange stain, which
assesses chromatin condensation. We found that the test
drugs, including vinca alkaloids (vincristine and vinblas-
tine), increased acridine orange staining of BME cell
nuclei, indicating that the drugs induced BME cell apop-
tosis. Inhibition of apoptosis (and the promotion of
endothelial cell survival) is important in the process of
angiogenesis. Several anti-angiogenic agents such as
angiostatin and endostatin have been reported to inhibit
angiogenesis in part by inducing endothelial cell apoptosis
[8, 9]. Results from this study further indicate that these
drugs have apoptotic activity which is likely to contribute
to their anti-angiogenic effect.
For in vitro angiogenesis studies, bovine microvascular
endothelial (BME) cells were cultured on the surface of 3-
dimensional type 1 collagen gels. Under control conditions,
BME cells remain on the surface of the gels, forming a
confluent monolayer. Growth factors (bFGF alone or
bFGF ? VEGF) induced BME cells to invade the under-
lying collagen matrix, within which they form networks of
capillary-like tubular structures, a phenomenon that closely
mimics the angiogenic process occurring in vivo. In pre-
vious studies, it was shown that bFGF and VEGF induce
BME cell invasion and tube formation in a collagen gel
invasion assay [23–25].
Our findings indicate that cytoskeletal-disrupting agents
tested (taxol, vincristine, vinblastine, colchicine, nocodaz-
ole and cytochalasin D), inhibit angiogenesis in vitro with
more potency than the DNA-damaging drugs, with the
exception of 2-ME. The vinca alkaloids, vincristine and
vinblastine, were the most potent inhibitors of angiogene-
sis, followed by taxol.
Taxol has been reported to exhibit anti-angiogenic
activity in vitro at doses that are well below the maximum
tolerated dose. In addition, vincristine, vinblastine, col-
chicine and nocodazole were shown in this study to inhibit
angiogenesis at noncytotoxic doses.
In general, the anti-proliferative effects induced by most
chemotherapeutic agents are associated with cell cycle
arrest and induction of apoptosis. Interestingly, vincristine,
vinblastine, colchicine and nocodazole induced an inhibi-
tion of cell growth at doses which did not result in
significant apoptosis. At these cytostatic doses, the drugs
inhibited angiogenesis in vitro.
A few case studies have reported on the use of vin-
cristine to treat hemangiomas, although its mechanism of
action has not been reported. It seems plausible that the
positive results observed in hemangioma patients following
treatment with vincristine may be due in part to its potent
anti-angiogenic activity.
Furthermore, vinblastine, colchicine, nocodazole as well
as taxol may have potential in the treatment of juvenile
hemangiomas, as they are more potent at inhibiting angi-
ogenesis than bleomycin. Further studies will focus on the
effects of combinations of these drugs on angiogenesis in
vitro and on hemangioma development in experimental
models in vivo.
Table 4 A summary of the effects of test drugs on the different parameters measured
Drug Cell growth
(IC50)
Cell migrationa Apoptosisb In vitro angiogenesis (IC50)
Bleomycin 0.105 lM 66.7 lM 6.677 lM 11.850 lM
Mitomycin C 0.149 lM NI 2.990 lM 2.340 lM
2-Methoxyestradiol 0.398 lM 10.0 lM 0.010 lM 0.400 lM
Taxol 0.040 lM 0.100 lM 0.010 lM 0.010 lM
Vincristine 0.004 lM 0.001 lM 0.011 lM 0.860 nM
Vinblastine 0.690 nM 0.011 lM 0.011 lM 0.870 nM
Colchicine 0.032 lM 0.100 lM 1.000 lM 0.016 lM
Nocodazole 0.031 lM 10.0 lM 1.000 lM 0.017 lM
Cytochalasin D 0.063 lM 0.100 lM ND 0.017 lM
a Dose at which significant inhibition of cell migration was observed
b Dose at which a significant number of BME cells were induced to undergo apoptosis
NI No inhibition of cell migration was observed at tested doses
ND Not determined
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